NICE recommends new CAR-T treatment for lymphoma for some patients on NHS

Some patients with relapsed or refractory mantle cell lymphoma will now be able to access a new CAR-T treatment, which uses their own re-engineered white blood cells to attack cancer cells, through the NHS.1 The new treatment has been made available after recommendation from the National Institute for Health and Care Excellence (NICE). The guidance, issued on 19 January, says that Tecartus (also known as autologous anti-CD19-transduced CD3+) can be …